Medrx
¥58
6
+¥0+0% 06:24 Today
Statistics
Day High
59
Day Low
56
52W High
225
52W Low
48
Volume
1,226,500
Avg. Volume
1,822,338
Mkt Cap
3.5B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
6NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-8.76
-6.54
-4.33
-2.11
Expected EPS
N/A
Actual EPS
N/A
Financials
-312.8%Profit Margin
Unprofitable257.92MRevenue
-806.76MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow 4586.TSE. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
H.U. Group
4544.TSE
Mkt Cap157.33B
Takeda Pharmaceutical
4502.TSE
Mkt Cap6.05T
Chugai Pharmaceutical
4519.TSE
Mkt Cap6.03T
OtsukaLtd.
4578.TSE
Mkt Cap2.43T
Eisai
4523.TSE
Mkt Cap1.69T
Shionogi &.
4507.TSE
Mkt Cap2.12T
Astellas Pharma
4503.TSE
Mkt Cap3.68T
Daiichi Sankyo.
4568.TSE
Mkt Cap8.21T
Kyowa Kirin.
4151.TSE
Mkt Cap1.75T
Nippon Shinyaku.
4516.TSE
Mkt Cap517.95B
About
Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption systems. Their innovation centers on technologies such as the Ionic Liquid Transdermal System (ILTS) and the Nano-sized Colloid Transdermal System (NCTS). MedRx also actively researches the pain-free transdermal delivery of various substances, including vaccines, nucleic acid medicines, and protein medicines. Its diverse product pipeline includes MRX-4TZT, undergoing Phase I clinical trials for spastic paralysis, and MRX-9FLT, also in Phase I, designed to alleviate chronic, cancer-related, and severe pain. Additionally, MRX-7MLL for Alzheimer's disease and MRX-6LDT for chronic pain are both in pre-clinical development. A notable achievement is MRX-5LBT, which has successfully concluded clinical trials for treating postherpetic nerve pain.
Show more...
CEO
Yonehiro Matsumura
Employees
21
Country
Japan
ISIN
JP3921220004
Listings
0 Comments
Share your thoughts
FAQ
What is Medrx stock price today?▼
The current price of 4586.TSE is ¥58 JPY — it has increased by +0% in the past 24 hours. Watch Medrx stock price performance more closely on the chart.
What is Medrx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Tokyo Stock Exchange exchange Medrx stocks are traded under the ticker 4586.TSE.
Is Medrx stock price growing?▼
4586.TSE stock has fallen by -13.43% compared to the previous week, the month change is a -13.43% fall, over the last year Medrx has showed a -47.75% decrease.
What is Medrx market cap?▼
Today Medrx has the market capitalization of 3.5B
When is the next Medrx earnings date?▼
Medrx is going to release the next earnings report on November 06, 2026.
What were Medrx earnings last quarter?▼
4586.TSE earnings for the last quarter are -5.09 JPY per share, whereas the estimation was N/A JPY resulting in a N/A surprise. The estimated earnings for the next quarter are N/A JPY per share.
What is Medrx revenue for the last year?▼
Medrx revenue for the last year amounts to 257.92M JPY.
What is Medrx net income for the last year?▼
4586.TSE net income for the last year is -806.76M JPY.
How many employees does Medrx have?▼
As of September 04, 2026, the company has 21 employees.
In which sector is Medrx located?▼
Medrx operates in the Health & Wellness sector.
When did Medrx complete a stock split?▼
Medrx has not had any recent stock splits.
Where is Medrx headquartered?▼
Medrx is headquartered in Higashikagawa, Japan.